The Global Dystonia Drugs Market size is expected to reach $1.1 billion by 2028, rising at a market growth of 5.4% CAGR during the forecast period.
Dystonia is a movement disease characterized by involuntary muscle contractions that lead to repetitive sluggish motions or aberrant postures. This muscle contraction results in aberrant muscle motions and body positions. Various types of dystonia can affect a single muscle, a group of muscles, or all of the body's muscles. It is caused by illnesses such as brain injury at or around birth, certain infections, brain trauma, and other vascular abnormalities, including stroke, arteriovenous, and others.
Patients may experience unpleasant movements or tremors as a result. There is no specific treatment for dystonia. However, its symptoms can be alleviated with various drugs. Uncontrollable muscular contractions characterize the neurological movement disorder dystonia.It is a condition that has no age, ethnic, or racial borders; it can afflict children and people of all races and ethnicities from infancy to old age.
Dystonia is caused by faulty basal ganglia functioning, a deep brain region that controls movement coordination. These brain regions regulate the speed and fluidity of movement and avoid undesired motions. Dystonic patients may exhibit involuntary twisting, repeated motions, or aberrant postures and positions. This includes the arms, legs, trunk, face, and vocal cords.
The origin of dystonia is unknown, but it may entail alterations in many brain regions or their connectivity. Dystonia may be genetic, acquired, or idiopathic in origin (no known cause). Inherited illnesses are genetically transmitted. In acquired forms, dystonia is caused by brain damage or degeneration (e.g., following a brain injury or stroke) or drug exposure. There is no known cause and no anatomical injury or degeneration of the brain in idiopathic dystonia.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Pfizer, Inc., Novartis AG, Teva Pharmaceuticals Industries Ltd., AbbVie, Inc., F. Hoffmann-La Roche Ltd., Ipsen Pharma Biotech SAS, Hameln Pharma Gmbh (Siegfried Group, LLP), Amneal Pharmaceuticals, Inc., Merz Pharma GmbH & Co. KGaA, and Wellona Pharma.
Dystonia is a movement disease characterized by involuntary muscle contractions that lead to repetitive sluggish motions or aberrant postures. This muscle contraction results in aberrant muscle motions and body positions. Various types of dystonia can affect a single muscle, a group of muscles, or all of the body's muscles. It is caused by illnesses such as brain injury at or around birth, certain infections, brain trauma, and other vascular abnormalities, including stroke, arteriovenous, and others.
Patients may experience unpleasant movements or tremors as a result. There is no specific treatment for dystonia. However, its symptoms can be alleviated with various drugs. Uncontrollable muscular contractions characterize the neurological movement disorder dystonia.It is a condition that has no age, ethnic, or racial borders; it can afflict children and people of all races and ethnicities from infancy to old age.
Dystonia is caused by faulty basal ganglia functioning, a deep brain region that controls movement coordination. These brain regions regulate the speed and fluidity of movement and avoid undesired motions. Dystonic patients may exhibit involuntary twisting, repeated motions, or aberrant postures and positions. This includes the arms, legs, trunk, face, and vocal cords.
The origin of dystonia is unknown, but it may entail alterations in many brain regions or their connectivity. Dystonia may be genetic, acquired, or idiopathic in origin (no known cause). Inherited illnesses are genetically transmitted. In acquired forms, dystonia is caused by brain damage or degeneration (e.g., following a brain injury or stroke) or drug exposure. There is no known cause and no anatomical injury or degeneration of the brain in idiopathic dystonia.
COVID-19 Impact Analysis
The outbreak of COVID-19 has affected operations in the healthcare sector. Several industries, including various sub-domains of health care, have been forced to close temporarily due to COVID-19. In 2020, the market for dystonia drugsdeclined due to the economic slowdown triggered by COVID-19. Furthermore, COVID-19 impacted the supply chain in businesses such as healthcare, further restricting the market growth. However, with ease in the pandemic, businesses and supply chains are returning to normal, which is expected to aid the market in recovery.Market Growth Factors
Enhancement of pharmaceutical research and development
The federal government influences private spending on research and development through programs that increase the demand for prescription drugs, through policies (like spending for basic research and regulations on what must be demonstrated in clinical trials) that affect the supply of new medicines, and through policies (like vaccine recommendations) that affect both supply and demand. The growing R&D in the pharmaceutical industry globally is expected to enhance the effectiveness of dystonia drugs and their utilization, thereby boosting the market growth.Rise in the prevalence of neurological illnesses
According to new research from the World Health Organization (WHO), neurological illnessesimpact up to one billion people globally.Neurological diseases impact individuals in all nations, regardless of age, gender, level of education, or money. Around 6.8 million people die annually due to neurological illnesses. Access to adequate care is challenging for many individuals with neurological illnesses, their families, and care providers. Primary health care is the only access to medical care for many individuals.Despite the availability of highly effective, inexpensive medications, many people with neurological disordersremainuntreated. Health systems must be fortified to provide better treatment for individuals with neurological illnesses.
Market Restraining Factors
Vast amount of the population unable to receive necessary medical care.
According to new research from the World Bank and the World Health Organization, at least half of thepopulation lacks access to crucial health care. And each year, many households are forced into poverty because they must pay for their health care. Nowadays, 800 million people spend at least 10 percent of their household budgets on health-related expenses for themselves, a sick kid, or another family member. These costs are sufficient to force about 100 million people into extreme poverty, requiring them to live on $1.90 or less per day.Type Outlook
Based on type, the dystonia drugs market is segmented into anticonvulsants drugs, GABAergic agents, dopaminergic agents and others. The GABAergic agents segment dominated the dystonia drugs market with maximum revenue share in 2021. The growth is attributed to its benefits in treating dystonia, particularly cervical dystonia. In addition, the discovery of highly effective and potent GABAergic agent pharmaceuticals for treating dystonia, combined with its more comprehensive prescription by healthcare experts, isfueling the segment'sexpansion in the forecasted period.Route of Administration Outlook
On the basis of route of administration, the dystonia drugs market is divided into oral and injectable. The injectable segment procured a substantial revenue share in the dystonia drugs market in 2021. This is because of the rise in innovations in parenteral dosing and increased research and development for botulinum injections. Absorption of the medication, especially aqueous solutions, is rapid and uniform. There is arapid commencement of effect compared to the oral and subcutaneous methods. Injection intramuscularly bypasses the drug's first-pass metabolism.Distribution Channel Outlook
By distribution channel, the dystonia drugs market is classified into hospital pharmacies, online providers and drug stores & retail pharmacies. The drug stores & retail pharmacies segment witnessed the largest revenue share in the dystonia drugs market in 2021. This is due to its extensive chain of distribution networks and it being the oldest and most convenient channel for providing drugs to consumers.Retail pharmacists prepare and dispense drugs, counsel consumers on the proper use of medications, and inform them of potential drug interactions. Also, retail pharmacists advise clients regarding over-the-counter medications and general health concerns.Regional Outlook
Region-wise, the dystonia drugs market is analyzed across North America, Europe, Asia Pacific, and LAMEA. The North America region generated the highest revenue share in the dystonia drugs market in 2021. This is because ofthe growingoccurrences of dystonia and the rise in the prevalence of other neurological disorders that cause dystonia in the population.In addition, the presence of a well-established healthcare infrastructure, a high purchasing power, and an increase in the diagnosis and treatment of dystonia in the region.The presence of a large number of unmet healthcare demands and a favorable regulatory environment are projected to boost the market's expansion.The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Pfizer, Inc., Novartis AG, Teva Pharmaceuticals Industries Ltd., AbbVie, Inc., F. Hoffmann-La Roche Ltd., Ipsen Pharma Biotech SAS, Hameln Pharma Gmbh (Siegfried Group, LLP), Amneal Pharmaceuticals, Inc., Merz Pharma GmbH & Co. KGaA, and Wellona Pharma.
Scope of the Study
By Distribution Channel
- Drug Stores & Retail Pharmacies
- Hospital Pharmacies
- Online Providers
By Route of Administration
- Oral
- Injectable
By Type
- GABAergic Agents
- Dopaminergic Agents
- Anticonvulsants Drugs
- Others
By Geography
- North America
- US
- Canada
- Mexico
- Rest of North America
- Europe
- Germany
- UK
- France
- Russia
- Spain
- Italy
- Rest of Europe
- Asia Pacific
- China
- Japan
- India
- South Korea
- Singapore
- Malaysia
- Rest of Asia Pacific
- LAMEA
- Brazil
- Argentina
- UAE
- Saudi Arabia
- South Africa
- Nigeria
- Rest of LAMEA
Key Market Players
List of Companies Profiled in the Report:
- Pfizer, Inc.
- Novartis AG
- Teva Pharmaceuticals Industries Ltd.
- AbbVie, Inc.
- F.Hoffmann-La Roche Ltd.
- Ipsen Pharma Biotech SAS
- Hameln Pharma Gmbh (Siegfried Group, LLP)
- Amneal Pharmaceuticals, Inc.
- Merz Pharma GmbH & Co. KGaA
- Wellona Pharma
Unique Offerings
- Exhaustive coverage
- The highest number of Market tables and figures
- Subscription-based model available
- Guaranteed best price
- Assured post sales research support with 10% customization free
Table of Contents
Chapter 1. Market Scope & Methodology1.1 Market Definition
1.2 Objectives
1.3 Market Scope
1.4 Segmentation
1.4.1 Global Dystonia Drugs Market, by Distribution Channel
1.4.2 Global Dystonia Drugs Market, by Route of Administration
1.4.3 Global Dystonia Drugs Market, by Type
1.4.4 Global Dystonia Drugs Market, by Geography
1.5 Methodology for the research
Chapter 2. Market Overview
2.1 Introduction
2.1.1 Overview
2.1.1.1 Market composition & scenario
2.2 Key Factors Impacting the Market
2.2.1 Market Drivers
2.2.2 Market Restraints
Chapter 3. Global Dystonia Drugs Market by Distribution Channel
3.1 Global Drug Stores & Retail Pharmacies Market by Region
3.2 Global Hospital Pharmacies Market by Region
3.3 Global Online Providers Market by Region
Chapter 4. Global Dystonia Drugs Market by Route of Administration
4.1 Global Oral Market by Region
4.2 Global Injectable Market by Region
Chapter 5. Global Dystonia Drugs Market by Type
5.1 Global GABAergic Agents Market by Region
5.2 Global Dopaminergic Agents Market by Region
5.3 Global Anticonvulsants Drugs Market by Region
5.4 Global Others Market by Region
Chapter 6. Global Dystonia Drugs Market by Region
6.1 North America Dystonia Drugs Market
6.1.1 North America Dystonia Drugs Market by Distribution Channel
6.1.1.1 North America Drug Stores & Retail Pharmacies Market by Country
6.1.1.2 North America Hospital Pharmacies Market by Country
6.1.1.3 North America Online Providers Market by Country
6.1.2 North America Dystonia Drugs Market by Route of Administration
6.1.2.1 North America Oral Market by Country
6.1.2.2 North America Injectable Market by Country
6.1.3 North America Dystonia Drugs Market by Type
6.1.3.1 North America GABAergic Agents Market by Country
6.1.3.2 North America Dopaminergic Agents Market by Country
6.1.3.3 North America Anticonvulsants Drugs Market by Country
6.1.3.4 North America Others Market by Country
6.1.4 North America Dystonia Drugs Market by Country
6.1.4.1 US Dystonia Drugs Market
6.1.4.1.1 US Dystonia Drugs Market by Distribution Channel
6.1.4.1.2 US Dystonia Drugs Market by Route of Administration
6.1.4.1.3 US Dystonia Drugs Market by Type
6.1.4.2 Canada Dystonia Drugs Market
6.1.4.2.1 Canada Dystonia Drugs Market by Distribution Channel
6.1.4.2.2 Canada Dystonia Drugs Market by Route of Administration
6.1.4.2.3 Canada Dystonia Drugs Market by Type
6.1.4.3 Mexico Dystonia Drugs Market
6.1.4.3.1 Mexico Dystonia Drugs Market by Distribution Channel
6.1.4.3.2 Mexico Dystonia Drugs Market by Route of Administration
6.1.4.3.3 Mexico Dystonia Drugs Market by Type
6.1.4.4 Rest of North America Dystonia Drugs Market
6.1.4.4.1 Rest of North America Dystonia Drugs Market by Distribution Channel
6.1.4.4.2 Rest of North America Dystonia Drugs Market by Route of Administration
6.1.4.4.3 Rest of North America Dystonia Drugs Market by Type
6.2 Europe Dystonia Drugs Market
6.2.1 Europe Dystonia Drugs Market by Distribution Channel
6.2.1.1 Europe Drug Stores & Retail Pharmacies Market by Country
6.2.1.2 Europe Hospital Pharmacies Market by Country
6.2.1.3 Europe Online Providers Market by Country
6.2.2 Europe Dystonia Drugs Market by Route of Administration
6.2.2.1 Europe Oral Market by Country
6.2.2.2 Europe Injectable Market by Country
6.2.3 Europe Dystonia Drugs Market by Type
6.2.3.1 Europe GABAergic Agents Market by Country
6.2.3.2 Europe Dopaminergic Agents Market by Country
6.2.3.3 Europe Anticonvulsants Drugs Market by Country
6.2.3.4 Europe Others Market by Country
6.2.4 Europe Dystonia Drugs Market by Country
6.2.4.1 Germany Dystonia Drugs Market
6.2.4.1.1 Germany Dystonia Drugs Market by Distribution Channel
6.2.4.1.2 Germany Dystonia Drugs Market by Route of Administration
6.2.4.1.3 Germany Dystonia Drugs Market by Type
6.2.4.2 UK Dystonia Drugs Market
6.2.4.2.1 UK Dystonia Drugs Market by Distribution Channel
6.2.4.2.2 UK Dystonia Drugs Market by Route of Administration
6.2.4.2.3 UK Dystonia Drugs Market by Type
6.2.4.3 France Dystonia Drugs Market
6.2.4.3.1 France Dystonia Drugs Market by Distribution Channel
6.2.4.3.2 France Dystonia Drugs Market by Route of Administration
6.2.4.3.3 France Dystonia Drugs Market by Type
6.2.4.4 Russia Dystonia Drugs Market
6.2.4.4.1 Russia Dystonia Drugs Market by Distribution Channel
6.2.4.4.2 Russia Dystonia Drugs Market by Route of Administration
6.2.4.4.3 Russia Dystonia Drugs Market by Type
6.2.4.5 Spain Dystonia Drugs Market
6.2.4.5.1 Spain Dystonia Drugs Market by Distribution Channel
6.2.4.5.2 Spain Dystonia Drugs Market by Route of Administration
6.2.4.5.3 Spain Dystonia Drugs Market by Type
6.2.4.6 Italy Dystonia Drugs Market
6.2.4.6.1 Italy Dystonia Drugs Market by Distribution Channel
6.2.4.6.2 Italy Dystonia Drugs Market by Route of Administration
6.2.4.6.3 Italy Dystonia Drugs Market by Type
6.2.4.7 Rest of Europe Dystonia Drugs Market
6.2.4.7.1 Rest of Europe Dystonia Drugs Market by Distribution Channel
6.2.4.7.2 Rest of Europe Dystonia Drugs Market by Route of Administration
6.2.4.7.3 Rest of Europe Dystonia Drugs Market by Type
6.3 Asia Pacific Dystonia Drugs Market
6.3.1 Asia Pacific Dystonia Drugs Market by Distribution Channel
6.3.1.1 Asia Pacific Drug Stores & Retail Pharmacies Market by Country
6.3.1.2 Asia Pacific Hospital Pharmacies Market by Country
6.3.1.3 Asia Pacific Online Providers Market by Country
6.3.2 Asia Pacific Dystonia Drugs Market by Route of Administration
6.3.2.1 Asia Pacific Oral Market by Country
6.3.2.2 Asia Pacific Injectable Market by Country
6.3.3 Asia Pacific Dystonia Drugs Market by Type
6.3.3.1 Asia Pacific GABAergic Agents Market by Country
6.3.3.2 Asia Pacific Dopaminergic Agents Market by Country
6.3.3.3 Asia Pacific Anticonvulsants Drugs Market by Country
6.3.3.4 Asia Pacific Others Market by Country
6.3.4 Asia Pacific Dystonia Drugs Market by Country
6.3.4.1 China Dystonia Drugs Market
6.3.4.1.1 China Dystonia Drugs Market by Distribution Channel
6.3.4.1.2 China Dystonia Drugs Market by Route of Administration
6.3.4.1.3 China Dystonia Drugs Market by Type
6.3.4.2 Japan Dystonia Drugs Market
6.3.4.2.1 Japan Dystonia Drugs Market by Distribution Channel
6.3.4.2.2 Japan Dystonia Drugs Market by Route of Administration
6.3.4.2.3 Japan Dystonia Drugs Market by Type
6.3.4.3 India Dystonia Drugs Market
6.3.4.3.1 India Dystonia Drugs Market by Distribution Channel
6.3.4.3.2 India Dystonia Drugs Market by Route of Administration
6.3.4.3.3 India Dystonia Drugs Market by Type
6.3.4.4 South Korea Dystonia Drugs Market
6.3.4.4.1 South Korea Dystonia Drugs Market by Distribution Channel
6.3.4.4.2 South Korea Dystonia Drugs Market by Route of Administration
6.3.4.4.3 South Korea Dystonia Drugs Market by Type
6.3.4.5 Singapore Dystonia Drugs Market
6.3.4.5.1 Singapore Dystonia Drugs Market by Distribution Channel
6.3.4.5.2 Singapore Dystonia Drugs Market by Route of Administration
6.3.4.5.3 Singapore Dystonia Drugs Market by Type
6.3.4.6 Malaysia Dystonia Drugs Market
6.3.4.6.1 Malaysia Dystonia Drugs Market by Distribution Channel
6.3.4.6.2 Malaysia Dystonia Drugs Market by Route of Administration
6.3.4.6.3 Malaysia Dystonia Drugs Market by Type
6.3.4.7 Rest of Asia Pacific Dystonia Drugs Market
6.3.4.7.1 Rest of Asia Pacific Dystonia Drugs Market by Distribution Channel
6.3.4.7.2 Rest of Asia Pacific Dystonia Drugs Market by Route of Administration
6.3.4.7.3 Rest of Asia Pacific Dystonia Drugs Market by Type
6.4 LAMEA Dystonia Drugs Market
6.4.1 LAMEA Dystonia Drugs Market by Distribution Channel
6.4.1.1 LAMEA Drug Stores & Retail Pharmacies Market by Country
6.4.1.2 LAMEA Hospital Pharmacies Market by Country
6.4.1.3 LAMEA Online Providers Market by Country
6.4.2 LAMEA Dystonia Drugs Market by Route of Administration
6.4.2.1 LAMEA Oral Market by Country
6.4.2.2 LAMEA Injectable Market by Country
6.4.3 LAMEA Dystonia Drugs Market by Type
6.4.3.1 LAMEA GABAergic Agents Market by Country
6.4.3.2 LAMEA Dopaminergic Agents Market by Country
6.4.3.3 LAMEA Anticonvulsants Drugs Market by Country
6.4.3.4 LAMEA Others Market by Country
6.4.4 LAMEA Dystonia Drugs Market by Country
6.4.4.1 Brazil Dystonia Drugs Market
6.4.4.1.1 Brazil Dystonia Drugs Market by Distribution Channel
6.4.4.1.2 Brazil Dystonia Drugs Market by Route of Administration
6.4.4.1.3 Brazil Dystonia Drugs Market by Type
6.4.4.2 Argentina Dystonia Drugs Market
6.4.4.2.1 Argentina Dystonia Drugs Market by Distribution Channel
6.4.4.2.2 Argentina Dystonia Drugs Market by Route of Administration
6.4.4.2.3 Argentina Dystonia Drugs Market by Type
6.4.4.3 UAE Dystonia Drugs Market
6.4.4.3.1 UAE Dystonia Drugs Market by Distribution Channel
6.4.4.3.2 UAE Dystonia Drugs Market by Route of Administration
6.4.4.3.3 UAE Dystonia Drugs Market by Type
6.4.4.4 Saudi Arabia Dystonia Drugs Market
6.4.4.4.1 Saudi Arabia Dystonia Drugs Market by Distribution Channel
6.4.4.4.2 Saudi Arabia Dystonia Drugs Market by Route of Administration
6.4.4.4.3 Saudi Arabia Dystonia Drugs Market by Type
6.4.4.5 South Africa Dystonia Drugs Market
6.4.4.5.1 South Africa Dystonia Drugs Market by Distribution Channel
6.4.4.5.2 South Africa Dystonia Drugs Market by Route of Administration
6.4.4.5.3 South Africa Dystonia Drugs Market by Type
6.4.4.6 Nigeria Dystonia Drugs Market
6.4.4.6.1 Nigeria Dystonia Drugs Market by Distribution Channel
6.4.4.6.2 Nigeria Dystonia Drugs Market by Route of Administration
6.4.4.6.3 Nigeria Dystonia Drugs Market by Type
6.4.4.7 Rest of LAMEA Dystonia Drugs Market
6.4.4.7.1 Rest of LAMEA Dystonia Drugs Market by Distribution Channel
6.4.4.7.2 Rest of LAMEA Dystonia Drugs Market by Route of Administration
6.4.4.7.3 Rest of LAMEA Dystonia Drugs Market by Type
Chapter 7. Company Profiles
7.1 Pfizer, Inc.
7.1.1 Company Overview
7.1.2 Financial Analysis
7.1.3 Regional & Segmental Analysis
7.1.4 Research & Development Expense
7.2 Novartis AG
7.2.1 Company Overview
7.2.2 Financial Analysis
7.2.3 Segmental and Regional Analysis
7.2.4 Research & Development Expense
7.3 Teva Pharmaceutical Industries Ltd.
7.3.1 Company Overview
7.3.2 Financial Analysis
7.3.3 Regional Analysis
7.3.4 Research & Development Expenses
7.3.5 Recent strategies and developments:
7.3.5.1 Product Launches and Product Expansions:
7.4 AbbVie, Inc.
7.4.1 Company Overview
7.4.2 Financial Analysis
7.4.3 Regional Analysis
7.4.4 Research & Development Expense
7.5 F. Hoffmann-La Roche Ltd.
7.5.1 Company Overview
7.5.2 Financial Analysis
7.5.3 Segmental and Regional Analysis
7.5.4 Research & Development Expense
7.6 Ipsen Pharma Biotech SAS
7.6.1 Company Overview
7.6.2 Financial Analysis
7.6.3 Segmental and Regional Analysis
7.6.4 Research & Development Expense
7.7 Hameln Pharma Gmbh (Siegfried Group, LLP)
7.7.1 Company Overview
7.7.2 Financial Analysis
7.7.3 Research & Development Expenses
7.8 Amneal Pharmaceuticals, Inc.
7.8.1 Company Overview
7.8.2 Financial Analysis
7.8.3 Segmental Analysis
7.8.4 Research & Development Expenses
7.9 Merz Pharma GmbH & Co. KGaA
7.9.1 Company Overview
7.9.2 Recent strategies and developments:
7.9.2.1 Approvals and Trials:
7.10. Wellona Pharma
7.10.1 Company Overview
Companies Mentioned
- Pfizer, Inc.
- Novartis AG
- Teva Pharmaceuticals Industries Ltd.
- AbbVie, Inc.
- F. Hoffmann-La Roche Ltd.
- Ipsen Pharma Biotech SAS
- Hameln Pharma Gmbh (Siegfried Group, LLP)
- Amneal Pharmaceuticals, Inc.
- Merz Pharma GmbH & Co. KGaA
- Wellona Pharma
Methodology
LOADING...
